Want to see FATE full AI Analyst Report?
FATE Stock Chart & Stats
$2.41
-$0.11(-4.37%)
At close: 4:00 PM EDT
$2.41
-$0.11(-4.37%)
Day’s Range― - ―
52-Week Range$0.91 - $3.23
Previous CloseN/A
Volume1.04M
Average Volume (3M)3.99M
Market Cap
$326.37M
Enterprise Value$46.00
Total Cash (Recent Filing)$174.82M
Total Debt (Recent Filing)$76.78M
Price to Earnings (P/E)―
Beta2.73
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding116,559,190
10 Day Avg. Volume2,352,050
30 Day Avg. Volume3,987,154
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)17.56
P/FCF Ratio-1.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.24Price Target Upside117.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$5.27M
Bulls Say, Bears Say
Bulls Say
IPSC Off-the-shelf PlatformFate’s iPSC-based, off-the-shelf approach is a durable competitive advantage: it enables scalable manufacturing, multi-patient runs and potentially lower per-dose cost versus autologous cell therapy. That manufacturing leverage supports longer-term commercial scalability across indications.
Advancing To Registrational Phase 2A planned Phase 2 registrational trial represents a structural de-risking step versus exploratory studies: positive registrational data can enable label-seeking submissions, catalyze partnerships, and justify investment in commercial infrastructure if efficacy and safety are confirmed.
Shareholder And Governance BackingStrong shareholder votes and governance actions signal alignment with management and support for equity-based retention. Auditor ratification and board continuity improve governance credibility, which helps attract partners and talent over the medium term.
Bears Say
High Cash BurnSustained large negative operating and free cash flow creates persistent financing need. Over the next 2–6 months this increases dilution risk or forces debt financing, constraining strategic optionality and potentially slowing development timelines if capital access tightens.
Weak Revenue And MarginsVery small, falling revenue coupled with negative gross profit and wide net losses indicate operations are not yet self-sustaining. Structural lack of product-derived revenue means long-term value depends entirely on clinical success and external funding, raising execution risk.
Eroding Equity BaseMaterial decline in shareholders' equity from prior years reflects cumulative losses and dilution, reducing the balance-sheet buffer. With limited internal cash generation this weakens financial resilience and increases vulnerability to adverse trial or funding outcomes.
Fate Therapeutics News
FATE FAQ
What was Fate Therapeutics Inc’s price range in the past 12 months?
Fate Therapeutics Inc lowest stock price was $0.91 and its highest was $3.23 in the past 12 months.
What is Fate Therapeutics Inc’s market cap?
Fate Therapeutics Inc’s market cap is $326.37M.
When is Fate Therapeutics Inc’s upcoming earnings report date?
Fate Therapeutics Inc’s upcoming earnings report date is Oct 29, 2026 which is in 78 days.
How were Fate Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Fate Therapeutics Inc overvalued?
According to Wall Street analysts Fate Therapeutics Inc’s price is currently Undervalued.
Does Fate Therapeutics Inc pay dividends?
Fate Therapeutics Inc does not currently pay dividends.
What is Fate Therapeutics Inc’s EPS estimate?
Fate Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fate Therapeutics Inc have?
Fate Therapeutics Inc has 116,559,190 shares outstanding.
What happened to Fate Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Fate Therapeutics Inc?
Currently, no hedge funds are holding shares in FATE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.24 (117.55% Upside)
$5.24 (117.55% Upside)
Blogger Sentiment
Neutral
FATE Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 188.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $305.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.53%
Trailing 12-Months
Company Description
Fate Therapeutics Inc
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
FATE Stock 12 Month Forecast
Average Price Target
$5.24
▲(117.55% Upside)
Technical Analysis
Ownership Overview
12.77% Insiders
12.63% Mutual Funds
3.61% Other Institutional Investors
65.41% Public Companies and
Individual Investors